Dose- and exposure response analysis of glycopyrrolate (GP) metered dose inhaler (MDI) to support optimal dosing in patients with COPD for combination product development

C. Reisner, C. Orevillo, E. St. Rose, H. Granko, C. Jomphe, M. Beliveau, J. F. Marier (Redwood City, St. Louis, United States Of America)

Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Session: Drug delivery and pharmacokinetics II
Session type: Thematic Poster Session
Number: 4538
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Reisner, C. Orevillo, E. St. Rose, H. Granko, C. Jomphe, M. Beliveau, J. F. Marier (Redwood City, St. Louis, United States Of America). Dose- and exposure response analysis of glycopyrrolate (GP) metered dose inhaler (MDI) to support optimal dosing in patients with COPD for combination product development. Eur Respir J 2010; 36: Suppl. 54, 4538

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Sub-microgram dose formulations for dose ranging studies with long acting bronchodilators and their fixed dose combination using metered dose inhalers (MDIs)
Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders
Year: 2013

Dose- and exposure-response modeling to support development of formoterol fumarate (FF) metered dose inhaler (MDI) for COPD
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010

COPD exacerbation rates by month in the ETHOS trial with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels
Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more
Year: 2020


Formoterol provides comparable bronchodilatation when delivered via dry powder (DPI) and metered dose inhalers (MDI) in adult asthma patients
Source: Eur Respir J 2005; 26: Suppl. 49, 339s
Year: 2005

Comparison of the long-term efficacy and safety of ipratropium bromide (IB) delivered by a new soft mist inhaler (SMI) versus conventional metered dose inhaler (MDI) in COPD patients
Source: Eur Respir J 2001; 18: Suppl. 33, 69s
Year: 2001

Low dose salmeterol/fluticasone propionate combination (SFC) via metered dose inhaler (MDI) improves asthma control and quality of life in patients not well controlled on inhaled steroids (ICS)
Source: Eur Respir J 2002; 20: Suppl. 38, 47s
Year: 2002

Seasonal variation in COPD exacerbation rates: budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial
Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD
Year: 2020




Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) delivered by a new soft mist inhaler (SMI) or a conventional metered dose inhaler (MDI) in COPD patients
Source: Eur Respir J 2001; 18: Suppl. 33, 70s
Year: 2001

Differences in patient perceived side effects (PPSE) of inhaled corticosteroids (ICS) between metered dose inhalers (MDI) and dry powder inhalers (DPI)
Source: Eur Respir J 2003; 22: Suppl. 45, 474s
Year: 2003

Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis
Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more
Year: 2020


Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) inhaled from a new soft mist inhaler (SMI) and from a conventional metered dose inhaler (MDI) in asthma patients
Source: Eur Respir J 2001; 18: Suppl. 33, 70s
Year: 2001

Non-inferior efficacy of hydrofluoroalkane (HFA) salmeterol (SALM) metered dose inhaler (MDI) compared to salmeterol chlorofluorocarbon (CFC) in adolescent & adult patients with persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 583s
Year: 2004

Comparison of the safety relating to paradoxical bronchoconstriction of ipratropium bromide (IB) alone or combined with fenoterol hydrobromide (FEN) inhaled from a new soft mist inhaler (SMI) and from a conventional metered dose inhaler (CFC-MDI) in
Source: Eur Respir J 2002; 20: Suppl. 38, 246s
Year: 2002

Asthma control with a breath-actuated pressurised metered dose inhaler (BAI) and prevalence of oral candidiasis: a prescribing claims study of 1701 patients prescribed a traditional pressurised metered dose inhaler (MDI) plus spacer or a BAI
Source: Eur Respir J 2002; 20: Suppl. 38, 78s
Year: 2002

Objective measurement of inhalation profiles in patients using metered dose inhalers (MDIs)
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011

Comparison of proficiency of pressurized metered dose inhaler (pMDI) use with asthma control
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008


Pharmacokinetics (PK) of a single dose AZD7594 administered intravenously (IV), orally, and inhaled via two dry powder inhalers (DPI) and a pressurized metered-dose inhaler (pMDI)
Source: International Congress 2017 – Pulmonary drug and devices delivery
Year: 2017

Late Breaking Abstract - Impact of eosinophil levels on lung function and exacerbation benefits with co-suspension delivery technology budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) in COPD (KRONOS study subgroup analysis)
Source: International Congress 2018 – Integrated care and non-pharmacological management of COPD
Year: 2018


A comparison of the efficacy of salmeterol/fluticasone propionate combination (SF) with beclometasone dipropionate (BDP) delivered via metered dose inhaler (MDI) in patients not well controlled on bronchodilators alone
Source: Eur Respir J 2001; 18: Suppl. 33, 53s
Year: 2001

Training patients on how to use metered dose inhaler (MDI) by using the 2Tone will improve asthma quality of life (AQOL)
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II
Year: 2008